Literature DB >> 17586694

Plexiform-like lesions and increased tissue factor expression in a rat model of severe pulmonary arterial hypertension.

R James White1, David F Meoli, Robert F Swarthout, Dara Y Kallop, Irfan I Galaria, Jennifer L Harvey, Christine M Miller, Burns C Blaxall, Carla M Hall, Richard A Pierce, Carlyne D Cool, Mark B Taubman.   

Abstract

Severe pulmonary arterial hypertension (PAH) occurs in idiopathic form and in association with diverse diseases. The pathological hallmarks are distal smooth muscle hypertrophy, obliteration of small pulmonary arteriole lumens, and disorganized cellular proliferation in plexiform lesions. In situ thrombosis is also observed. A detailed understanding of the disease progression has been hampered by the absence of an animal model bearing all the pathological features of human disease. To create a model with these characteristics, we gave young (200-g) rats monocrotaline 1 wk following left pneumonectomy; controls with vehicle treatment or sham operation were also studied. In experimental rats, pulmonary arteries had distal smooth muscle hypertrophy and proliferative perivascular lesions. The lesions had a plexiform appearance, occurred early in disease development, and were composed of cells expressing endothelial antigens. Three-dimensional microangiography revealed severe vascular pruning and disorganized vascular networks. We found that expression of tissue factor (TF), the membrane glycoprotein that initiates coagulation, facilitates angiogenesis, and mediates arterial injury in the systemic circulation, was increased in the pulmonary arterioles and plexiform-like lesions of the rats. TF was also heavily expressed in the vessels and plexiform lesions of humans with pulmonary arterial hypertension. We conclude that plexiform-like lesions can be reproduced in rats, and this model will facilitate experiments to address controversies about the role of these lesions in PAH. Increased TF expression may contribute to the prothrombotic diathesis and vascular cell proliferation typical of human disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17586694     DOI: 10.1152/ajplung.00321.2006

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  50 in total

1.  Matrix metalloproteinase-9 and plasminogen activator inhibitor-1 are associated with right ventricular structure and function: the MESA-RV Study.

Authors:  Steven M Kawut; R Graham Barr; W Craig Johnson; Harjit Chahal; Harikrishna Tandri; Aditya Jain; Michael R Bristow; Jorge R Kizer; Emilia Bagiella; Joao A C Lima; David A Bluemke
Journal:  Biomarkers       Date:  2010-10-05       Impact factor: 2.658

Review 2.  Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies.

Authors:  Stephen L Archer; E Kenneth Weir; Martin R Wilkins
Journal:  Circulation       Date:  2010-05-11       Impact factor: 29.690

3.  Improved pulmonary vascular reactivity and decreased hypertrophic remodeling during nonhypercapnic acidosis in experimental pulmonary hypertension.

Authors:  Helen Christou; Ossama M Reslan; Virak Mam; Alain F Tanbe; Sally H Vitali; Marlin Touma; Elena Arons; S Alex Mitsialis; Stella Kourembanas; Raouf A Khalil
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-01-27       Impact factor: 5.464

4.  Hemodynamic and histologic characterization of a swine (Sus scrofa domestica) model of chronic pulmonary arterial hypertension.

Authors:  Abraham Rothman; Robert G Wiencek; Stephanie Davidson; William N Evans; Humberto Restrepo; Valeri Sarukhanov; Amanda Rivera-Begeman; David Mann
Journal:  Comp Med       Date:  2011-06       Impact factor: 0.982

Review 5.  Reversible or irreversible remodeling in pulmonary arterial hypertension.

Authors:  Seiichiro Sakao; Koichiro Tatsumi; Norbert F Voelkel
Journal:  Am J Respir Cell Mol Biol       Date:  2009-12-11       Impact factor: 6.914

Review 6.  Plexiform Arteriopathy in Rodent Models of Pulmonary Arterial Hypertension.

Authors:  Brandon L Carman; Dan N Predescu; Roberto Machado; Sanda A Predescu
Journal:  Am J Pathol       Date:  2019-03-26       Impact factor: 4.307

Review 7.  Sex, Gender, and Sex Hormones in Pulmonary Hypertension and Right Ventricular Failure.

Authors:  James Hester; Corey Ventetuolo; Tim Lahm
Journal:  Compr Physiol       Date:  2019-12-18       Impact factor: 9.090

8.  Severe pulmonary arterial hypertension induced by SU5416 and ovalbumin immunization.

Authors:  Shiro Mizuno; Laszlo Farkas; Aysar Al Husseini; Daniela Farkas; Jose Gomez-Arroyo; Donatas Kraskauskas; Mark R Nicolls; Carlyne D Cool; Herman J Bogaard; Norbert F Voelkel
Journal:  Am J Respir Cell Mol Biol       Date:  2012-07-27       Impact factor: 6.914

9.  Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease.

Authors:  Kari E Roberts; Michael B Fallon; Michael J Krowka; Robert S Brown; James F Trotter; Inga Peter; Hocine Tighiouart; James A Knowles; Daniel Rabinowitz; Raymond L Benza; David B Badesch; Darren B Taichman; Evelyn M Horn; Steven Zacks; Neil Kaplowitz; Steven M Kawut
Journal:  Am J Respir Crit Care Med       Date:  2009-02-12       Impact factor: 21.405

10.  A comparison of echocardiography to invasive measurement in the evaluation of pulmonary arterial hypertension in a rat model.

Authors:  Juha W Koskenvuo; Rachel Mirsky; Yan Zhang; Franca S Angeli; Sarah Jahn; Tero-Pekka Alastalo; Nelson B Schiller; Andrew J Boyle; Kanu Chatterjee; Teresa De Marco; Yerem Yeghiazarians
Journal:  Int J Cardiovasc Imaging       Date:  2010-02-07       Impact factor: 2.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.